A multibillion-dollar partnership between AbbVie and Genmab risks being soured by a lawsuit claiming misappropriation of trade secrets. Specifically, it focuses on the use of disaccharides to ...

Concurrently, Genmab is embroiled in a legal dispute with AbbVie Inc (NYSE:ABBV)., which has accused the company of misappropriating trade secrets related to antibody-drug conjugates. Genmab has ...

AbbVie will pay Danish antibody specialist Genmab $750 million upfront for rights to a series of drugs headed by epcoritamab, a bispecific antibody in development for non-Hodgkin’s lymphoma.

The share buy-back program Company Announcement AbbVie Inc. files complaint against Genmab in the U.S. District Court for the Western District of Washington (Seattle)Genmab categorically refutes ...

Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced the successful conclusion of the eleventh Annual Genedata Partner Symposium (March 31?April 1 ...

Concurrently, Genmab is embroiled in a legal dispute with AbbVie Inc (NYSE:ABBV)., which has accused the company of misappropriating trade secrets related to antibody-drug conjugates. Genmab has ...

Investing.com -- Bernstein analysts have downgraded Genmab A/S (CSE:GMAB) to an "underperform" rating from "market perform,” in a note dated Tuesday. Shares of the Danish biotechnology company ...

Genmab (GMAB) announced that the European Commission has granted marketing authorization for TIVDAK, an antibody-drug conjugate, as monotherapy ...

Genmab (GMAB) ADRs traded lower on Tuesday after Bernstein downgraded the Danish biotech to Underperform from Market Perform, arguing that its stock has yet to fully reflect the upcoming patent ...

We recently published a list of 7 Most Profitable Biotech Stocks To Buy Right Now. In this article, we are going to take a look at whereGenmab A/S (NASDAQ:GMAB) stands against other most ...